5 October 2022 in Research Results in Pharmacology
Introduction: The process of protein synthesis is a vital process for all kingdoms of life. The ribosome is a ribonucleoprotein complex that reads the genetic code, from messenger RNA (mRNA) to produce proteins and to tightly regulate and ensure cells growth. The fact that numerous diseases are caused by defect during the ribosome biogenesis is important to understand this pathway. Materials and methods: We have analyzed the literature for ribosome biogenesis and its links with different diseases which have been found. Results and discussion: We have discussed the key aspect of human ribosome biogenesis and its links to diseases. We have also proposed the potential of applying this knowledge to the development of a ribosomal stress-based cancer therapy. Conclusion: Major challenges in the future will be to determine factors which play a pivotal role during ribosome biogenesis. Therefore, more anti-cancer drugs and gene therapy for genetic diseases will be developed against ribosomal biogenesis in the coming years. Graphical
30 October 2026 in BioTechnologia
The ribosome is a ribonucleoprotein complex that translates messenger RNA (mRNA) sequences into polypeptide chains. Ribosome biogenesis is a highly complex process with a pivotal role in many cellular processes, including proliferation, differentiation, apoptosis, development, and malignant transformation. Nonsense mutation introduces premature termination codons (PTCs), resulting in early termination of translation and synthesis of truncated proteins. Readthrough therapy aims to enhance suppression and consequently restore the production of full-length proteins. This approach has yielded considerable success over the years and has shown promising outcomes in many disorders associated with nonsense mutations; however, applying this approach to treat skin diseases remains challenging. This review summarizes current investigations on nonsense suppression strategies pertaining to epidermolysis bullosa. We focus on aminoglycosides that induce PTC readthrough, the small molecule PTC124 (ataluren), and inhibitors of nonsense-mediated mRNA decay. We also examine some emerging compounds that target the translational machinery and may become relevant for future nonsense mutation suppression therapy.